Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 14, 2018

SELL
$35.44 - $63.76 $11.9 Million - $21.3 Million
-334,381 Closed
0 $0
Q3 2017

Nov 14, 2017

SELL
$53.83 - $67.75 $28,691 - $36,110
-533 Reduced 0.16%
334,381 $21.7 Million
Q2 2017

Aug 14, 2017

BUY
N/A
334,914
334,914 $18.1 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $685M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.